| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
|
Mayer-Hamblett, Nicole
|
|
|
11 |
10 |
p. 932-944
|
artikel
|
| 2 |
Air pollution, climate change, and lung health in Europe
|
The Lancet Respiratory Medicine,
|
|
|
11 |
10 |
p. 851
|
artikel
|
| 3 |
Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?
|
Menis, Jessica
|
|
|
11 |
10 |
p. 857-859
|
artikel
|
| 4 |
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
|
Lu, Shun
|
|
|
11 |
10 |
p. 905-915
|
artikel
|
| 5 |
Claudio Castanos—leader in cystic fibrosis care in Argentina
|
Kirby, Tony
|
|
|
11 |
10 |
p. 871
|
artikel
|
| 6 |
Coal-fired power plant pollution in South Africa
|
Makoni, Munyaradzi
|
|
|
11 |
10 |
p. 866
|
artikel
|
| 7 |
COVID-19 boosters versus primary series: update to a living review
|
Wu, Nana
|
|
|
11 |
10 |
p. e87-e88
|
artikel
|
| 8 |
Earlier start to COVID-19 autumn vaccine programmes
|
Burki, Talha
|
|
|
11 |
10 |
p. 867
|
artikel
|
| 9 |
End-of-life care in cystic fibrosis in the era of new therapies
|
Dellon, Elisabeth P
|
|
|
11 |
10 |
p. 861-863
|
artikel
|
| 10 |
Extracorporeal cardiopulmonary resuscitation: not why, but how
|
Kalra, Rajat
|
|
|
11 |
10 |
p. 853-855
|
artikel
|
| 11 |
Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: a comparative meta-analysis and trial sequential analysis
|
Low, Christopher Jer Wei
|
|
|
11 |
10 |
p. 883-893
|
artikel
|
| 12 |
Geographical inequities in access to speech and language therapy critical care services in UK
|
Kelly, Eileen
|
|
|
11 |
10 |
p. e85-e86
|
artikel
|
| 13 |
Global efforts to improve tuberculosis drug availability
|
Burki, Talha
|
|
|
11 |
10 |
p. 868
|
artikel
|
| 14 |
Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials
|
Blette, Bryan S
|
|
|
11 |
10 |
p. 873-882
|
artikel
|
| 15 |
Nangibotide for precision immunomodulation in septic shock and COVID-19
|
Neupane, Maniraj
|
|
|
11 |
10 |
p. 855-857
|
artikel
|
| 16 |
Progress and challenges in tuberculosis control in Sudan
|
Shuaib, Yassir Adam
|
|
|
11 |
10 |
p. 869-870
|
artikel
|
| 17 |
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
|
François, Bruno
|
|
|
11 |
10 |
p. 894-904
|
artikel
|
| 18 |
Seeing the funny side of anaesthetics
|
Ranscombe, Peter
|
|
|
11 |
10 |
p. 872
|
artikel
|
| 19 |
Surrogate endpoints in pulmonary arterial hypertension trials
|
Hoeper, Marius M
|
|
|
11 |
10 |
p. 852-853
|
artikel
|
| 20 |
The past 10 years of cystic fibrosis treatment: the road to cure
|
Castaños, Claudio
|
|
|
11 |
10 |
p. 864-865
|
artikel
|
| 21 |
Trial emulation with observational data in cystic fibrosis
|
Davies, Gwyneth
|
|
|
11 |
10 |
p. 859-861
|
artikel
|
| 22 |
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy
|
Hisert, Katherine B
|
|
|
11 |
10 |
p. 916-931
|
artikel
|
| 23 |
Video laryngoscopy is not the nemesis of direct laryngoscopy
|
Peyton, James M
|
|
|
11 |
10 |
p. e84
|
artikel
|
Tijdschrift beschrijving